Low Blood Levels of Selenium, Selenoprotein P and GPx3 are Associated with Accelerated Biological Aging: Results from the Berlin Aging Study II (BASE-II)

Valentin Max Vetter^{1,a}, Kamil Demircan^{2,a}, Jan Homann³, Thilo Samson Chillon², Michael Mülleder⁴, Orr Shomroni⁴, Elisabeth Steinhagen-Thiessen¹, Markus Ralser^{4,5}, Christina M. Lill^{3,6}, Lars Bertram⁷, Lutz Schomburg^{2,b}, Ilja Demuth^{1,8,b}

^a Valentin Max Vetter and Kamil Demircan are joint first authors. ^b Lutz Schomburg and Ilja Demuth are joint last authors.

¹ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolic Diseases (including Division of Lipid Metabolism), Biology of Aging working group, Augustenburger Platz 1, 13353 Berlin, Germany

² Institute for Experimental Endocrinology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, D-10115, Berlin, Germany

³ Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany

⁴ Core Facility High Throughput Mass Spectrometry, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

⁵ The Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, UK

⁶ Aging Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK

⁷ Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany

⁸ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, 13353 Berlin, Germany

Corresponding Author: Ilja Demuth (Ph.D.) Charité - Universitätsmedizin Berlin Lipid Clinic at the Interdisciplinary Metabolism Center, Biology of Aging Group Augustenburger Platz 1 13353 Berlin Email: ilja.demuth@charite.de Phone: ++49 30 450 569 143 FAX: ++49 30 450 566 904

Abstract

Introduction

Biological age reflects inter-individual differences in biological function and capacity beyond chronological age. Biological age can be estimated by DNA methylation age (DNAmA) and its deviation from chronological age, DNAmA acceleration (DNAmAA). Low levels of serum selenium, selenoprotein P (SELENOP), and the selenocysteine-containing glutathione peroxidase 3 (GPx3) are associated with adverse health outcomes and selenium supplementation is discussed as an anti-aging intervention.

Methods

In this study we analyzed 1,568 older participants from the Berlin Aging Study II (mean age +/- SD: 68.8 +/- 3.7 years, 51% women). DNAmA was estimated from genome-wide DNA methylation data using the Horvath, GrimAge, and DunedinPACE algorithms. Serum selenium levels were measured by total reflection X-ray fluorescence (TXRF) spectroscopy. SELENOP was measured by ELISA and GPx3 was derived from a larger set of mass spectrometry proteomics data.

Results

Participants with deficient serum selenium levels ($<90\mu g/L$) had a higher rate of biological aging (DunedinPACE, p=0.01, n=865). This association remained statistically significant after adjustment for age, sex, BMI, smoking, and genetic ancestry (β =-0.02, SE=0.01, 95%CI: - 0.034 to -0.004, n=757). Compared to the highest quartile, participants in the lowest quartile of SELENOP levels showed an accelerated biological aging rate (DunedinPACE, β =-0.03, SE=0.01, 95%CI: -0.051 to -0.008, n=740, fully adjusted model). Similarly, after adjustment for covariates, accelerated biological age was found in participants within the lowest GPx3 quartile compared to participants in the fourth quartile (DunedinPACE, p=<0.001 and GrimAge, p<0.001).

Conclusion

Our study suggests that low levels of selenium biomarkers are associated with accelerated biological aging measured as DNAmA. This effect was not substantially changed after adjustment for known covariates.

Introduction

Over the past few decades the average lifespan increased faster than the healthspan, which resulted in a growing burden of late-life diseases (1, 2). However, there are substantial interindividual differences in the pace of aging and some people remain disease-free and in good health until old age. Although some lifestyle habits were shown to impact some areas of aging (3) they do not fully explain the observed between-person differences. Hence, the identification of additional factors promoting a "healthy aging" trajectory would potentially benefit many. One recent, and often considered very useful (4, 5), biomarker to quantify difference in biological aging is DNA methylation age (DNAmA, epigenetic age) estimated from DNA methylation data by so called epigenetic clocks (6). The difference between epigenetic and chronological age, DNAmA acceleration (DNAmAA), was shown in previous studies to be associated with mortality as well as with numerous age-related diseases and phenotypes (6). Due to the ability of these clocks to assess the biological age of an individual they are increasingly used as endpoints for the evaluation of anti-aging interventions (reviewed in (7-11)).

In related research, one factor discussed in the context of healthy aging is selenium, an essential trace element that regulates thyroid hormone metabolism, antioxidative, and redox processes through incorporation into selenoproteins (12), which needs to be present in sufficient levels to exert its physiological function. Selenium status and its cellular availability (determined by dietary intake and its absorption) directly regulate expression and activity of selenoproteins (13). Selenium status can be determined by assessment of serum selenium biomarkers such as total selenium, the selenium transporter selenoprotein P (SELENOP), or glutathione peroxidase 3 (GPx3), a selenocysteine-containing extracellular antioxidant enzyme (14). Emerging clinical evidence indicates an association between a deficient status of these selenium biomarkers and outcomes of mortality and chronic diseases

4

of older age, i.e., measures of an increased pace of aging (15-19). The direct association between selenium biomarkers and epigenetic aging, however, remains understudied. The relationship between blood selenium levels and DNAmA was analyzed in two previous studies, which revealed promising links between selenium levels and biological aging (20, 21). However, both studies were of small sample size (n=93 (20) and n=276 (21)), and analyzed only total selenium, but none of the other selenium-related variables. In this study, we analyzed the association between biological aging as determined with three DNAmA estimators (i.e. Horvath (22), GrimAge (23), and DunedinPACE (24)) total serum selenium, and two complementary protein biomarkers, SELENOP, GPx3, in a large cohort of 1,568 older participants from the Berlin Aging Study II (BASE-II).

Methods

Study population

The Berlin Aging Study II (BASE-II) is a multi-disciplinary study that aims to identify factors promoting healthy aging trajectories. BASE-II comprises 1,671 participants (60 - 85 years), who were recruited in the metropolitan area of Berlin, Germany from 2009 to 2014. Older participants who reported the intake of selenium supplements were excluded (n=103) resulting in a final dataset of up to 1,568 participants. A detailed description of the study's cohort profile was published before and can be found in ref. (25).

DNA methylation age (DNAmA), DNAmA acceleration (DNAmAA) and pace of aging

The participants' epigenetic age was estimated from DNA methylation data utilizing three "first-generation" clocks (Horvath (22), Hannum (26), 7-CpG (27)), two "second-generation" clocks (PhenoAge (28), GrimAge (23)) and DunedinPACE (24), and a third-generation clock. DNAm data for the 7-CpG clock was measured by Single Nucleotide Prime Extension (SNuPE) in 1471 samples. The laboratory protocol is described in detail elsewhere (27). All other clocks were derived from DNAm data measured by the "Infinium MethylationEPIC" array (Illumina, Inc., USA), data of which was available for n=1,030 participants. Additional information on laboratory procedures and data processing can be found in reference (29). The DunedinPACE clock was calculated based using the methods described in the original publication (24).

DNA methylation age acceleration (DNAmAA) was calculated for all clocks (except for DunedinPACE) as residuals of a linear regression of DNAmA on chronological age accounting for leukocyte cell distribution (neutrophils, monocytes, lymphocytes, and eosinophils in G/l).

Assessment of selenium, SELENOP and GPx3

The selenium biomarkers *SELENOP* and *GPx3* were measured at the Institute of Experimental Endocrinology, Charité University Hospital, Berlin, from serum samples that were taken during the same blood draw that produced the sample for the DNA isolation. Selenium status was measured by total reflection X-ray fluorescence (TXRF) spectroscopy as described in detail before (30, 31). SELENOP was measured from serum samples with a sandwich ELISA method using monoclonal human antibodies. Additional information on how selenium and SELENOP were measured in BASE-II were previously described in detail (32). GPx3 intensities were derived from proteomics data at baseline was measured by Liquid chromatography-mass spectrometry (LC-MS), using data independent acquisition (Supplementary Methods).

Covariates

Chronological age, sex, and smoking behavior (in packyears) were assessed during a one-onone interview with trained study personnel. Body weight and height were measured with the measuring station (763, SECA, Germany). Genetic ancestry was controlled for by using the first four principal components from a principal component analysis on genome-wide SNP genotyping data. A detailed description of the procedures applied to calculate this co-variate were published previously (33). Leukocyte cell distribution was measured from samples obtained at the same blood-draw that was used for DNA isolation in an accredited clinical biochemistry laboratory (MVZ Labor 28 GmbH, Berlin, Germany) by automated standard methods (flow cytometry).

Statistical analysis

Statistical analyses were conducted in R (version 4.3.1) (34). Descriptive statistics were calculated with R's tableone package (35). Linear regression analyses were calculated with R's *lm* and *lm.beta* function (lm.beta package (36)) to examine the relationship between

DNAmA estimators (dependent variable) and selenium biomarkers (independent variables). Figures were drawn with the ggplot2 package. Selenium biomarker outliers were defined as $<25^{\text{th}}$ percentile -1.5*SD and >the 75th percentile +1.5*SD. This resulted in the exclusion of n=46 (serum selenium), n=111 (SELENOP), and n=151 (GPx3) observations. Participants with missing values in phenotypic data were excluded from the respective analyses (available case analyses). Statistical significance was defined at α =5%. Due to the exploratory nature of this study, no adjustment was made for multiple testing.

Results

Study population and characteristics

The sample analyzed in this study comprised 1,568 BASE-II participants with a mean age of 69 years (SD=3.4, range 60-85 years). Sex was almost equally distributed (51% women). 656 (48.3%) participants had a selenium level of 90μ g/L or lower, i.e. displayingselenium-deficiency. Study population characteristics are shown in Table 1.

Association of selenium with biological age acceleration

Visual inspections of the distribution of serum selenium levels vs. DNAmAA estimated by the GrimaAge and DunedinPACE clocks suggested possible non-linear associations (Figure 1). Therefore, in the next step we examined epigenetic age stratified by selenium deficiency ($<90\mu g/L$) and found a statistically significantly higher pace of aging measured by DunedinPACE in selenium-deficient participants (SMD=0.2, p=0.01, t-test, Figure 1 F). DunedinPACE remained higher in selenium-deficient participants after the adjustment for known covariates (chronological age, sex, BMI, smoking, genetic ancestry) in linear regression analyses (β =-0.02, SE=0.007, p=0.012, n=757, Table 2). Sex-stratified analyses showed that these results were mainly driven by the subgroup of men (Supplementary Table 2).

Association of SELENOP with biological age

Low SELENOP levels were similarly associated with accelerated GrimAge DNAmAA and DunedinPACE (Figure 2). Assuming a non-linear relationship based on the scatterplot (Figure 2 A-C), SELENOP values were categorized into quartiles. A statistically significantly higher pace of biological aging (DunedinPACE) was measured in participants of the lowest quartile compared to participants in the highest quartile (SMD = 0.21, p=0.032, Figure 2 F). This association remained statistically significant after covariate adjustment (β =-0.03, SE=0.011,

p=0.007, Table 3). After covariate adjustment the findings were only statistically significant in the subgroup of women (Supplementary Table 4 and 5).

Association of GPx3 with biological age

Finally, compared to the lowest quartile, participants in the fourth quartile had a higher age acceleration estimated from the GrimAge clock (SMD = 0.41, p<0.001) and DunedinPACE clock (SMD = 0.54, p<0.001, Figure 3). These associations persisted to be statistically significant after covariate adjustment (p<=0.002, Table 4). Sex-specific analyses are presented in Supplementary Table 7 and 8.

Discussion

In this study, we analyzed the association between serum biomarkers, namely total serum selenium, SELENOP, GPx3 and biological age measured by epigenetic clocks in 865 participants of BASE-II. Lower values in all three selenium biomarkers were associated with an increased pace of aging measured with the DunedinPACE clock. This association was independent from covariates included in the linear regression analysis.

The stepwise increase in the strength of association from the first- to the third-generation clock is likely due to the methodological approach used for their development with the later clocks potentially including CpG sites that better reflect the underlying aging process (37). Furthermore, newer DNAmA clocks are more sensitive towards exogenous effects (20). This trend was also observed with clinical phenotypes (7, 24, 38).

Our findings are in line with results published by Cheng and colleagues (20) who found a statistically significant association between serum selenium levels and DunedinPACE in a sample of 93 participants. In contrast, we could not validate the association between selenium levels and PhenoAge DNAmAA reported by the same authors (Supplementary Table 2). Furthermore, regarding our non-significant associations of selenium levels with earlier DNAmA clocks, our results are consistent with findings from a cohort of 276 older Chinese men and women that showed no statistically significant association between selenium and the first- and second-generation clocks (21).

Boyer and colleagues did not find a consistent association between urine selenium and any epigenetic age estimation in linear regression models in an American Indian population of 2,301 participants (Strong Heart Study, SHS) (37). However, when analyzing the effect of the total metal mixture using Bayesian Kernel Machine Regression, a non-linear association with PhenoAge, GrimAge and DunedinPACE was found (37). The difference in these results compared to our study may arise from the choice of matrix used to determine selenium status. Specifically, the selenium status in the SHS was replete (37), whereas BASE-II participants

showed a borderline selenium-deficiency. The lack of effects observed in SHS may also be attributable to the saturated expression of selenoproteins, and thus likely reflecting a threshold effect as commonly observed for selenium and health outcomes.

Our analyses do not allow to draw any conclusions on cause-effect relationships between selenium levels and accelerated biological aging. However, our results corroborate recent findings on aging phenotypes assessed by other clinical and phenotypical outcomes that show an association between selenium biomarkers and mortality (15, 19, 39), cardiovascular outcomes (16, 17, 39), and several cancer entities (14, 40-42). Moreover, an effect of selenium levels on epigenetic age appears biologically plausible since it is well established that selenium levels in rodents, cell-lines (human, mouse) and human tissue impact the methylome (reviewed in (43)).

Strengths of this study include the large sample size with an equal representation of men and women and a high degree of data completeness for the study parameters and potential confounders. Furthermore, this is the first study that examines additional selenium biomarkers, i.e., SELENOP and GPx3, in addition to selenium levels. The differing half-lives of these biomarkers ensure low risk of misclassification due to e.g., prior supplementation or enriched dietary selenium intake.

However, our study also has a few limitations. Firstly, as outlined above, the cross-sectional analyses presented in this study do not allow to draw any conclusions about causality or direction of effect. Secondly, the analyzed sample is of above-average health. Therefore, it is possible that the effects reported here are underestimated since BASE-II participants are generally healthier. In addition, this limits the generalizability of our results to the background population of mainly European elderly subjects with borderline sufficient selenium status residing in a metropolitan area. Thirdly, due to the explorative nature of this analysis, no adjustment for multiple testing was made. Fourthly, no detailed information about dosage and frequency of potential additional selenium intake by nutritional supplements was available.

Therefore, all participants who reported selenium supplementation were excluded and evaluating effects of selenium supplementation on biological age was precluded.

Conclusion

Our study shows that selenium biomarkers are moderately associated with accelerated biological aging in a European-based dataset. These results support previous findings that suggest health benefits of sufficient selenium levels. Randomized controlled trials are needed to evaluate the potential therapeutic benefit of selenium supplementation and its effect on biological age acceleration.

Acknowledgments

Funding

This work was supported by grants of the Deutsche Forschungsgemeinschaft (grant number 460683900 to ID and LB, and CRC/TR 296 "LocoTact" to LS), the ERC (as part of the "Lifebrain" project to LB), and the Cure Alzheimer's Fund (as part of the "CIR- CUITS" consortium to LB), the German Federal Ministry of Education and Research as part of the National Research Initiative 'Mass Spectrometry in Systems Medicine' (MSCoreSys), under grant agreement number 01EP2201 (to MR) and 16LW0239K (to MM), the Berlin University Alliance (BUA Link Lab, 501_Massenspektrometrie, 501_Linklab), as well as the German Cancer Consortium (DKTK) under grant BE01 1020000483 (to MR). C.M.L. was supported by the Heisenberg program of the German Research Foundation (DFG; LI 2654/4-1). This article uses data from the Berlin Aging Study II (BASE-II). BASE-II was supported by the German Federal Ministry of Education and Research under grant numbers #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01GL1716A, and #01GL1716B.

Conflict of interest

LS holds shares of selenOmed GmbH, a company involved in Se status assessment; no other relationships or activities that could appear to have influenced the submitted work are indicated.

Other authors: none.

Data Availability

Due to concerns for participant privacy, data are available only upon reasonable request. Please contact Ludmila Mu ller, scientific coordinator, at lmueller@mpib-berlin.mpg.de, for additional information.

Ethics

All participants gave written informed consent. The Ethics Committee of the Charité – Universitätsmedizin Berlin approved the study (approval numbers EA2/029/09 and EA2/144/16). The study was conducted in accordance with the Declaration of Helsinki and was registered in the German Clinical Trials Registry as DRKS00009277.

Author contributions:

Conceptualization: V.M.V., K.D., T.S.C.; L.S., I.D.; Data curation: V.M.V., J.H., M.M., O.S., L.B., I.D.; Formal analysis: V.M.V.; Funding acquisition: E.S.-T.; M.R., L.B., L.S., I.D.; Resources: E.S.-T.; M.R., L.B., L.S., I.D.; Supervision: C.L., M.R., L.B., L.S., I.D.; Visualization: V.M.V.; Writing: V.M.V, K.D., I.D.; Reviewed and approved the manuscript: all authors.

References:

 Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of aging. Nature. 2018;561(7721):45-56.

2. Beard JR, Officer A, De Carvalho IA, Sadana R, Pot AM, Michel J-P, et al. The World report on aging and health: a policy framework for healthy aging. The lancet.

2016;387(10033):2145-54.

3. Li Y, Schoufour J, Wang DD, Dhana K, Pan A, Liu X, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ (Clinical research ed). 2020;368:16669.

Jylhava J, Pedersen NL, Hagg S. Biological Age Predictors. EBioMedicine.
 2017;21:29-36.

5. Li X, Ploner A, Wang Y, Magnusson PK, Reynolds C, Finkel D, et al. Longitudinal trajectories, correlations and mortality associations of nine biological ages across 20-years follow-up. Elife. 2020;9:e51507.

6. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of aging. Nature Reviews Genetics. 2018:1.

7. Waziry R, Ryan CP, Corcoran DL, Huffman KM, Kobor MS, Kothari M, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging. 2023;3(3):248-57.

8. Vetter VM, Sommerer Y, Kalies CH, Spira D, Bertram L, Demuth I. Vitamin D supplementation is associated with slower epigenetic aging. GeroScience. 2022.

9. Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging cell. 2019;18(6):e13028.

10. Fiorito G, Caini S, Palli D, Bendinelli B, Saieva C, Ermini I, et al. DNA methylation □ based biomarkers of aging were slowed down in a two □ year diet and physical activity intervention trial: the DAMA study. Aging cell. 2021;20(10):e13439.

Moqri M, Herzog C, Poganik JR, Justice J, Belsky DW, Higgins-Chen A, et al.
 Biomarkers of aging for the identification and evaluation of longevity interventions. Cell.
 2023;186(18):3758-75.

12. Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: molecular pathways and physiological roles. Physiol Rev. 2014;94(3):739-77.

13. Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, et al. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. The American journal of clinical nutrition.

2010;92(3):525-31.

14. Demircan K, Bengtsson Y, Sun Q, Brange A, Vallon-Christersson J, Rijntjes E, et al. Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study. Redox Biol. 2021;47:102145.

15. Schöttker B, Holleczek B, Hybsier S, Köhrle J, Schomburg L, Brenner H. Strong associations of serum selenoprotein P with all-cause mortality and mortality due to cancer, cardiovascular, respiratory and gastrointestinal diseases in older German adults. Eur J Epidemiol. 2024.

Jujic A, Molvin J, Schomburg L, Hartmann O, Bergmann A, Melander O, et al.
 Selenoprotein P deficiency is associated with higher risk of incident heart failure. Free Radic
 Biol Med. 2023;207:11-6.

Schomburg L, Orho-Melander M, Struck J, Bergmann A, Melander O. Selenoprotein-P
 Deficiency Predicts Cardiovascular Disease and Death. Nutrients. 2019;11(8).

18. Qiu Z, Geng T, Wan Z, Lu Q, Guo J, Liu L, et al. Serum selenium concentrations and risk of all-cause and heart disease mortality among individuals with type 2 diabetes. The American journal of clinical nutrition. 2022;115(1):53-60.

19. Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008;168(4):404-10.

20. Cheng X, Wei Y, Wang R, Jia C, Zhang Z, An J, et al. Associations of essential trace elements with epigenetic aging indicators and the potential mediating role of inflammation. Redox Biology. 2023;67:102910.

 Xiao L, Zan G, Feng X, Bao Y, Huang S, Luo X, et al. The associations of multiple metals mixture with accelerated DNA methylation aging. Environmental Pollution.
 2021;269:116230.

Horvath S. DNA methylation age of human tissues and cell types. Genome biology.
 2013;14(10):R115.

23. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019;11(2):303.

24. Belsky DW, Caspi A, Corcoran DL, Sugden K, Poulton R, Arseneault L, et al.DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.

25. Bertram L, Bockenhoff A, Demuth I, Duzel S, Eckardt R, Li SC, et al. Cohort profile:
The Berlin Aging Study II (BASE-II). International journal of epidemiology. 2014;43(3):70312.

26. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Molecular cell.
2013;49(2):359-67.

27. Vetter VM, Meyer A, Karbasiyan M, Steinhagen-Thiessen E, Hopfenmuller W, Demuth I. Epigenetic clock and relative telomere length represent largely different aspects of aging in the Berlin Aging Study II (BASE-II). The journals of gerontology Series A, Biological sciences and medical sciences. 2018.

28. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573.

29. Vetter VM, Spieker J, Sommerer Y, Buchmann N, Kalies CH, Regitz-Zagrosek V, et al.DNA methylation age acceleration is associated with risk of diabetes complications.Communications Medicine. 2023;3(1):21.

30. Hughes DJ, Duarte-Salles T, Hybsier S, Trichopoulou A, Stepien M, Aleksandrova K, et al. Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. The American journal of clinical nutrition. 2016;104(2):406-14.

31. Stoppe C, McDonald B, Meybohm P, Christopher KB, Fremes S, Whitlock R, et al. Effect of high-dose selenium on postoperative organ dysfunction and mortality in cardiac surgery patients: the SUSTAIN CSX randomized clinical trial. JAMA surgery.

2023;158(3):235-44.

32. Hybsier S, Schulz T, Wu Z, Demuth I, Minich WB, Renko K, et al. Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for selenoprotein P. Redox Biology. 2017;11:403-14.

33. Vetter VM, Drewelies J, Sommerer Y, Kalies CH, Regitz-Zagrosek V, Bertram L, et al.
Epigenetic aging and perceived psychological stress in old age. Translational Psychiatry.
2022;12(1):410.

34. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria URL <u>https://wwwR-projectorg</u>. 2022.

35. Yoshida K. Bartel, A. tableone: Create "Table 1" to Describe Baseline Characteristics with or without Propensity Score Weights, version 0.13. 2, R Studio package; RStudio. Inc: Vienna, Austria. 2022.

Behrendt S. Im. beta Add standardized regression coefficients to linear-model-objects.R package version; 2023.

37. Boyer K, Domingo-Relloso A, Jiang E, Haack K, Goessler W, Zhang Y, et al. Metal mixtures and DNA methylation measures of biological aging in American Indian populations. Environment International. 2023;178:108064.

38. Sugden K, Caspi A, Elliott ML, Bourassa KJ, Chamarti K, Corcoran DL, et al. Association of pace of aging measured by blood-based DNA methylation with age-related cognitive impairment and dementia. Neurology. 2022;99(13):e1402-e13.

39. Al-Mubarak AA, Grote Beverborg N, Suthahar N, Gansevoort RT, Bakker SJL, Touw DJ, et al. High selenium levels associate with reduced risk of mortality and new-onset heart failure: data from PREVEND. Eur J Heart Fail. 2022;24(2):299-307.

40. Baker JR, Umesh S, Jenab M, Schomburg L, Tjønneland A, Olsen A, et al.
Prediagnostic Blood Selenium Status and Mortality among Patients with Colorectal Cancer in
Western European Populations. Biomedicines. 2021;9(11).

41. Sandsveden M, Nilsson E, Borgquist S, Rosendahl AH, Manjer J. Prediagnostic serum selenium levels in relation to breast cancer survival and tumor characteristics. Int J Cancer. 2020;147(9):2424-36.

42. Pietrzak S, Wójcik J, Scott RJ, Kashyap A, Grodzki T, Baszuk P, et al. Influence of the selenium level on overall survival in lung cancer. J Trace Elem Med Biol. 2019;56:46-51.

43. Speckmann B, Grune T. Epigenetic effects of selenium and their implications for health. Epigenetics. 2015;10(3):179-90.

Tables:

Variables	mean (SD), n (%)	Min	Max	n
Age (years)	68.79 (3.73)	60,16	84,63	1568
Sex (women)	799 (51.0)			1568
BMI (kg/m ²)	26.83 (4.19)	17,03	47,68	1534
Smoking (packyears)	10.51 (17.75)	0,00	148,00	1511
Serum Selenium (µg/L)	89.65 (17.38)	45,20	134,60	1357
Selenium deficiency (<90 µg/L)	656 (48.3)			1357
SELENOP (mg/L)	3.72 (0.83)	1,26	5,86	1324
GPx3 (intensity)	12.52 (0.27)	11,33	13,11	1209
7-CpG DNAmAA (years)	0.00 (6.97)	-22,93	26,61	1305
Horvath DNAmAA (years)	0.04 (4.27)	-14,71	17,90	853
Hannum DNAmAA (years)	-0.04 (3.48)	-10,90	19,15	853
PhenoAge DNAmAA (years)	0.03 (4.61)	-16,88	14,28	853
GrimAge DNAmAA (years)	0.01 (3.08)	-8,52	10,20	853
DunedinPACE (biol./chron.)	1.01 (0.11)	0,58	1,42	959

Table 1: Baseline characteristics of analyzed sample.

Table 2: Linear regression analysis of epigenetic age estimators on selenium status (deficient vs. sufficient) at baseline. Model 1 is unadjusted. Model 2 is adjusted for chronological age, sex, BMI, smoking (packyears), and the first four genetic principal components (PC1 to PC4).

Dependent Variable	Model	St. β	β	SE	р	lowCI	upCI	n
Horvath Clock	1	0.021	0.175	0.306	0.566	-0.425	0.775	782
	2	0.019	0.155	0.320	0.628	-0.473	0.783	684
GrimAge	1	0.010	0.065	0.222	0.771	-0.371	0.500	782
	2	-0.017	-0.104	0.208	0.619	-0.513	0.306	684
DunedinPACE	1	-0.087	-0.019	0.007	0.010	-0.033	-0.004	865
	2	-0.087	-0.019	0.007	0.012	-0.034	-0.004	757

Note: St. = Standardized; SE = Standard Error; p = p-value; lowCI = lower 95% confidence

interval; upCI = upper 95% confidence interval.

Table 3: Linear regression analysis of epigenetic age estimators on quartiles of SELENOP at baseline. Model 1 is unadjusted. Model 2 is adjusted for chronological age, sex, BMI, smoking (packyears), and the first four genetic principal components (PC1 to PC4). The first quartile is used as reference.

Dependent Variable	Model		St. β	β	SE	р	lowCI	upCI	n
Horvath DNAmAA	1	Q2	0.033	0.310	0.435	0.477	-0.545	1.164	765
		Q3	-0.003	-0.026	0.450	0.954	-0.909	0.857	765
		Q4	0.012	0.120	0.451	0.791	-0.766	1.005	765
	2	Q2	0.032	0.293	0.457	0.522	-0.605	1.191	667
		Q3	0.026	0.252	0.467	0.590	-0.666	1.169	667
		Q4	0.007	0.067	0.476	0.888	-0.867	1.001	667
GrimAge	1	Q2	0.033	0.224	0.314	0.476	-0.393	0.841	765
		Q3	-0.071	-0.514	0.325	0.114	-1.152	0.124	765
		Q4	0.004	0.028	0.326	0.932	-0.612	0.667	765
	2	Q2	0.032	0.220	0.298	0.460	-0.365	0.806	667
		Q3	-0.048	-0.345	0.305	0.258	-0.943	0.254	667
		Q4	0.002	0.015	0.310	0.962	-0.595	0.624	667
DunedinPACE	1	Q2	-0.076	-0.018	0.010	0.078	-0.039	0.002	848
		Q3	-0.065	-0.016	0.011	0.125	-0.038	0.005	848
		Q4	-0.096	-0.024	0.011	0.024	-0.045	-0.003	848
	2	Q2	-0.074	-0.018	0.011	0.089	-0.039	0.003	740
		Q3	-0.067	-0.017	0.011	0.119	-0.038	0.004	740
		Q4	-0.115	-0.030	0.011	0.007	-0.051	-0.008	740

Note: St. = Standardized; SE = Standard Error; p = p-value; lowCI = lower 95% confidence

interval; upCI = upper 95% confidence interval.

Table 4: Linear regression analysis of epigenetic age estimators on quartiles of GPx3 intensity (proteomics data) at baseline. Model 1 is unadjusted. Model 2 is adjusted for chronological age, sex, BMI, smoking (packyears), and the first four genetic principal components (PC1 to PC4). The first quartile is used as reference group.

Dependent Variable	Model		St. β	β	SE	р	lowCI	upCI	n
Horvath DNAmAA	1	Q2	-0.033	-0.322	0.462	0.487	-1.228	0.585	689
		Q3	-0.076	-0.772	0.471	0.102	-1.697	0.153	689
		Q4	-0.064	-0.628	0.458	0.171	-1.527	0.272	689
	2	Q2	-0.016	-0.151	0.478	0.753	-1.090	0.788	608
		Q3	-0.048	-0.475	0.489	0.332	-1.436	0.486	608
		Q4	-0.030	-0.284	0.485	0.558	-1.236	0.667	608
GrimAge	1	Q2	0.004	0.026	0.332	0.937	-0.625	0.677	689
		Q3	-0.059	-0.430	0.338	0.203	-1.094	0.233	689
		Q4	-0.176	-1.246	0.329	0.000	-1.892	-0.601	689
	2	Q2	-0.044	-0.313	0.310	0.313	-0.923	0.296	608
		Q3	-0.085	-0.628	0.318	0.048	-1.252	-0.005	608
		Q4	-0.136	-0.975	0.315	0.002	-1.593	-0.358	608
DunedinPACE	1	Q2	-0.006	-0.002	0.011	0.885	-0.023	0.020	764
		Q3	-0.044	-0.011	0.011	0.309	-0.033	0.010	764
		Q4	-0.218	-0.054	0.011	0.000	-0.076	-0.033	764
	2	Q2	-0.011	-0.003	0.011	0.801	-0.024	0.019	674
		Q3	-0.039	-0.010	0.011	0.369	-0.032	0.012	674
		Q4	-0.146	-0.037	0.011	0.001	-0.059	-0.015	674

Note: St. = Standardized; SE = Standard Error; p = p-value; lowCI = lower 95% confidence interval; upCI = upper 95% confidence interval.

Figures:



Figure 1: A-C: Scatterplots of serum selenium levels at baseline and biological age estimators. The x-axis is log-scaled. All available participants of the older age group are included. D-F: Boxplots of biological age estimators stratified by selenium status (deficient vs. sufficient. cut-off 90 μ g/L) at baseline. Statistical significance of difference between group means was assessed by t-test. Note: DNAmAA = DNA methylation age acceleration; biolog. = biological years; chron. = chronological years. Boxplots show the median, hinges (corresponding to 25th and 75th percentile) and whiskers (1.5*inter-quartile range (IQR)).



Figure 2: A-C: Scatterplots of SELENOP levels and biological age estimators. The x-axis is log-scaled. D-F: Boxplots of biological age estimators stratified by quartiles of SELENOP. Statistical significance of difference between group means was assessed by t-test. Note: DNAmAA = DNA methylation age acceleration; biolog. = biological years; chron. = chronological years. Boxplots show the median, hinges (corresponding to 25th and 75th percentile) and whiskers (1.5*inter-quartile range (IQR)).



Figure 3: A-C: Scatterplots of GPx3 intensity (proteomics data) and biological age estimators. The x-axis is log-scaled. D-F: Boxplots of biological age estimators stratified by quartiles of GPx3 intensity (proteomics data). Statistical significance of difference between group means was assessed by t-test. Note: DNAmAA = DNA methylation age acceleration; biolog. = biological years; chron. = chronological years. Boxplots show the median, hinges (corresponding to 25th and 75th percentile) and whiskers (1.5*inter-quartile range (IQR)).